Letter: Presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma-Reference-Cited by-同舟云学术

Letter: Presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma

Published:2024-04-21 Issue:11 Volume:59 Page:1462-1464
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

De Toni Enrico N.¹^ORCID,Mayerle Julia¹,Oehrle Bettina¹,Seidensticker Max²,Rimassa Lorenza³⁴,Philipp Alexander¹,Roessler Daniel¹,Khaled Najib Ben¹^ORCID

Affiliation:

1. Department of Medicine 2 University Hospital, LMU Munich Munich Germany

2. Department of Radiology University Hospital, LMU Munich Munich Germany

3. Department of Biomedical Sciences Humanitas University Pieve Emanuele (Milan) Italy

4. Medical Oncology and Hematology Unit, Humanitas Cancer Center IRCCS Humanitas Research Hospital Rozzano (Milan) Italy

Abstract

LINKED CONTENTThis article is linked to Jost‐Brinkmann et al papers. To view these articles, visit https://doi.org/10.1111/apt.17441 and https://doi.org/10.1111/apt.18008

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.17985

Reference6 articles.

1. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real‐world cohort

2. Review article: systemic treatment of hepatocellular carcinoma

3. On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study

4. Sequential systemic treatment in patients with hepatocellular carcinoma

5. IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor).

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Letter: Presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma. Authors' reply;Alimentary Pharmacology & Therapeutics;2024-05-06